Change Language

Select Language

Global Hyperlipidemia Drugs Market to Grow 2% During 2021-2026, Bolstered by the Emergence of Novel Drugs

Published on Nov 11, 2020

The latest report by IMARC Group, titled “Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, finds that the global hyperlipidemia drugs market exhibited stable growth during 2015-2020. Hyperlipidemia refers to a condition that causes abnormally high levels of fats or lipids in the blood. It is a common type of dyslipidemia that can be inherited or result from an unhealthy lifestyle and poor diet. The disorder may lead to cardiac stroke, peripheral vascular diseases, obesity, hypertension, and cardiovascular disorders(CVDs). Hyperlipidemia can be detected by performing a blood test called a lipid panel or lipid profile. Statins are the primary line of treatment in secondary hyperlipidemia caused by an unhealthy lifestyle. Some of the other common drugs used in the treatment of hyperlipidemia are bile acid sequestrants, PCSK9, and miscellaneous antihyperlipidemic agents, which help reduce the production of cholesterol in the liver. They also lower the number of lipids in the bloodstream and reduce inflammation and damage done to the cells.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global Hyperlipidemia Drugs Market Trends:

The global hyperlipidemia drugs market is primarily driven by the increasing awareness regarding the associated risks of CVDs and high cholesterol. Governments are introducing new guidelines redefining at-risk patient groups and recommending the use of anti-hyperlipidemics to lower the risk of these diseases. In addition to this, the upcoming patent expiration has resulted in the genericization of statin and cholesterol absorption inhibitors, which is significantly augmenting the market growth. Furthermore, the launch of innovative products, such as the development ofnovel drugs, which offer improved efficacy and safety profile, is positively impacting the market across the globe. Moreover, there has been extensive research and development (R&D) activities for developing innovative drugs. On account of these factors, the market is expected to exhibit a CAGR of 2% during the forecast period (2021-2026).

Market Summary:

  • Based on the drug type, the market has been segmented into statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, fibric acid derivatives, and others. Currently, statins dominate the market, holding the largest market share.  
  • On the basis of the end user, the market has been classified into hospitals, clinics, and others. Among these, hospitals represent the leadingend user.
  • Region-wise, Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others) exhibits a clear dominance in the market. Other regions are North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has been examined, with some of the key players being Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi S.A.


About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group

USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91-120-433-0800 )


Drop us an email at

sales@imarcgroup.com